New RNA vaccine aims to rev up immune therapy in Hard-to-Treat cancers
NCT ID NCT05264974
First seen Nov 01, 2025 · Last updated May 12, 2026 · Updated 27 times
Summary
This early-phase trial tests a custom-made RNA vaccine designed to help the immune system recognize and attack tumors in people with advanced melanoma or soft tissue sarcoma whose cancer has worsened despite standard immunotherapy. Up to 18 adults will receive three doses of the vaccine, made from their own tumor tissue, to see if it is safe and feasible. The goal is to make anti-PD-1 therapy more effective again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Florida
RECRUITINGGainesville, Florida, 32608, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.